PharmAbcine to Participate in Both J.P. Morgan Health Conference 2020 and Biotech Showcase in San Francisco, Ca, USA

PharmAbcine Inc. (KOSDAQ: 208340) announced today that Dr. Jin-San Yoo, the CEO of the company and other delegates will attend the 38th annual J.P. Morgan Healthcare Conference held at the Westin St. Francis Hotel on January 12-16 and Biotech Showcase at the Hilton San Francisco Union Square on January 13-15, 2020. During the week of conference, PharmAbcine will evaluate and discuss strategic partnership with a number of global pharmaceutical companies, global investment bankers, biopharma and innovative biotech companies.

Dr. Jin-San Yoo will present company’s clinical and pre-clinical developmental pipeline at Biotech Showcase. The details of the presentation are as follows:

Date: January 14, 2020

Time: 3:00 PM PST

Track: Yosemite C (Ballroom Level)

Venue: Hilton San Francisco Union Square.

Both the annual J.P. Morgan Health Conference and Biotech Showcase are the largest and most informative annual healthcare symposiums in the industry, bringing together industry leaders, emerging fast growing biopharmaceutical and life sciences companies, and members of investment community.

For more information about J.P. Morgan Health Conference and Biotech Showcase, please visit:

About PharmAbcine Inc.

PharmAbcine is a clinical-stage biotech company, listed in KOSDAQ stock market (208340), focusing on the development of fully human antibody (mAb) therapeutics, especially reputed for leading the development of next-generation multi-specifics. This multi-specific antibody technology can be achieved through our in-house novel technology development, namely DIG-Body, PIG-Body and TIG-Body. Using innovative discovery technology and excellent human resources, we provide a number of superlative immunotherapeutics for indications in immuno-oncology, immunology and ophthalmology.

PharmAbcine’s HuPhage library and innovative selection system are priceless proprietary assets. Additionally, our well-established 3G expression system ultimately helped concrete our stupendous reputation in the field of biopharma industry by allowing us to achieve the reinforcement and reproducibility of high levels of antibody production. On the basis of our highly maintained, advanced technical systems, we are pleased to provide high quality antibody generation services. Moreover, our high standards antibodies have allowed us to be actively involved in co-development with our partners and we are willing to expand co-development opportunities to other potential partners.

Under the collaboration with SAMSUNG MEDICAL CENTER, PharmAbcine has more than 300 patients-derived cancer stem cell libraries and an animal model system for evaluating internal pipeline development.

Selected pipeline:

TTAC-0001(olinvacimab): It is an anti-VEGFR2 fully human IgG with unique cross reactivity between mouse and human and has completed a Phase IIa recurrent glioblastoma multiforme (rGBM) trial in Australia in August 2017. It is currently in a phase 2 clinical trial in Australia and USA for bevacizumab-refractory rGBM patients. Being an anti-angiogenesis agent that has shown good safety profile and efficacy in rGBM patients, TTAC-0001 is a good candidate to develop combination therapy with other cancer therapeutics and we are currently running two phase 1b clinical trials with pembrolizumab in rGBM and mTNBC patients.

PMC-001, PMC-002 & 002R: They are a series of next generation bispecific antibody neutralizing both VEGFR2 and Ang2-TIE2 pathways. It has been shown to be more efficacious than monotherapy using bevacizumab or olinvacimab alone in preliminary studies.

PMC-122: A novel bispecific antibody neutralizing both PD1-PDL1 and SIRPα-CD47 pathways. We developed a strategy to maximize inhibiting the pathways in TME (tumour microenvironment) while minimizing the effects on RBC (both tumour cells and RBCs express CD47).

PMC-201: It is a next generation bispecific antibody neutralizing both VEGFR2 and Notch-DLL4. DLL4/Notch-1 pathway is involved in maintaining CSC’s (cancer stem cells) and thus, targeting both VEGFR2 and DLL4 can effectively block malignant proliferation, metastasis, as well as tumor recurrence caused by DLL4 positive CSCs.  In order to minimize any side effects associated with targeting DLL4, PMC-201 was built upon TTAC-0001 IgG backbone that is proven to be safe in cancer patients and it is designed to specifically bind to the DLL4 expressed on tumor cells. We confirmed PMC-201 has strong anti-tumor activities in tumor-bearing mice.

PMC-309: It is a fully human antibody targeting VISTA that is highly expressed on the surface of MDSCs (myeloid-derived suppressor cells) and TAMs (tumour-associated macrophages) present in the TME. We have multiple classes of anti-VISTA antibodies that are being characterized in different environment.

PMC-401S: It is a novel monospecific anti-Ang2 in ScFv (single chain variable fragment) format. By blocking Ang2-Tie2 pathway without affecting Ang1 binging to Tie2, it functions as an active vessel stabilizer. It showed great efficacy in age-related macular degeneration (AMD) and diabetic retinopathy (DR) animal models.

PMC-402: It is a Tie2 targeting antibody. Upon binding to the Tie2 as an agonist, it stabilizes leaky tumor vessels into functional ones and we are exploring a combination therapy of PMC-402 with other cancer therapeutics. It is also being developed to treat posterior segment eye diseases such as AMD and DR in ophthalmology.

PMC-005B: It neutralizes EGFR variant III (EGFRvIII). With its internalization property, it can be incorporated to develop ADC (antibody-drug conjugate), CAR-T (chimeric antigen receptor T cell) and CAR-NK (chimeric antigen receptor NK cell).

PMC-901: Bevacizumab biosimilar cell line with higher titer than originator

PMC-902: Aflibercept biosimilar cell line with higher titer than originator

For all the pipelines listed, we are open for out-licensing and co-development of combination therapy.

Additional information about PharmAbcine can be found on our website at


Yohan Jung


Back to news